Immunic exercises exclusive IMU-856 global license option from Daiichi
Category: #health  | By Mateen Dalal  | Date: 2020-01-10 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Immunic exercises exclusive IMU-856 global license option from Daiichi

Immunic, a renowned biopharmaceutical company focused on treating autoimmune and chronic inflammatory diseases, reportedly announced that its subsidiary, Immunic AG, has implemented its exclusive global license option for a group of compounds that are designated by it as IMU-856.

The company exercised this option under the terms of its license agreement and existing option with Japanese pharmaceutical company, Daiichi Sankyo.

The company plans to initiate a phase 1 clinical trial for this novel program during the first half of 2020. The IMU-856 is a small molecule, orally available modulator that aims at a yet undisclosed protein that works like a transcriptional regulator for the intestinal barrier function.

IMU-856 signifies a novel and potentially disruptive method to treat intestinal diseases. the molecule also is capable of restoring the intestinal barrier function and it would also maintain immunocompetency.

President and Chief Executive Officer of Immunic, Daniel Vitt, Ph.D., stated that practicing this option is a vital milestone, as it signifies that the company is convinced about the IMU-856’s preclinical safety profile. Further, the company is ready to move ahead and take the program in phase 1 clinical studies, which it intends to start in the first half of 2020.  

Vitt further added that the company’s recently showcased preclinical information reinforced its belief that IMU-856 has disease-modifying features for several intestinal diseases and shows potential significant benefits on present immunosuppressive therapies which tackles inflammation while unintentionally reducing the immune surveillance of the body.

Vitt also added that the company is hopeful that this phase 1, multiple and single ascending dose trials would serve as a vital step for IMU-856’s development as a safe therapy option for patients with gastrointestinal diseases through restoring intestinal barrier function without impairing the patient’s immune system.

Senior Executive Officer and Global Head of R&D at Daiichi Sankyo, Junichi Koga stated that the company is pleased that Immunic exercised the option for IMU-856. The company is dedicated to providing innovative medicines to patients throughout the world as fast as possible, either by itself or from strategic partnerships.

Koga further added that the company is confident that Immunic is its best partner and would quickly propel the development of this new compound for patients suffering from intestinal diseases.

 

Source credit: https://www.immunic-therapeutics.com/2020/01/08/immunic-exercises-its-option-for-the-exclusive-worldwide-license-to-imu-856-from-daiichi-sankyo-co-ltd/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...